Literature DB >> 17451629

Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia.

Niels Bergemann1, Peter Parzer, Benno Runnebaum, Franz Resch, Christoph Mundt.   

Abstract

BACKGROUND: Estrogen has been hypothesized to have a protective and antipsychotic-like effect in women at risk for schizophrenia. The aim of the present study was to evaluate the association between menstrual cycle and/or estrogen levels and psychotic symptoms in a sample of women with schizophrenia.
METHOD: One hundred and twenty-five premenopausal women with schizophrenia and regular menses were examined. The levels of 17beta-estradiol and other hormones of the gonadal axis were assessed in the follicular, peri-ovulatory, and luteal phases of the menstrual cycle. The effects of the menstrual cycle phase and/or the estradiol level on the Positive and Negative Syndrome Scale (PANSS) and the Brief Psychiatric Rating Scale (BPRS) scores were calculated by means of regression analyses.
RESULTS: Significant improvement in psychotic, but not depressive, symptoms was observed during the luteal phase, compared with other days of the menstrual cycle.
CONCLUSIONS: The present findings indicate that estradiol may have specific antipsychotic-like effects on the symptoms of schizophrenia. Thus further investigation into the therapeutic effect of estrogen may be worthwhile.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17451629     DOI: 10.1017/S0033291707000578

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  30 in total

1.  Risk/reward decision-making in schizophrenia: a preliminary examination of the influence of tobacco smoking and relationship to Wisconsin Card Sorting Task performance.

Authors:  Sarah W Yip; Kristi A Sacco; Tony P George; Marc N Potenza
Journal:  Schizophr Res       Date:  2009-03-09       Impact factor: 4.939

2.  Evidence of a sex-dependent restrictive epigenome in schizophrenia.

Authors:  Kayla A Chase; Cherise Rosen; Leah H Rubin; Benjamin Feiner; Anjuli S Bodapati; Hannah Gin; Edward Hu; Rajiv P Sharma
Journal:  J Psychiatr Res       Date:  2015-04-18       Impact factor: 4.791

3.  Effect of Adjunctive Estradiol on Schizophrenia Among Women of Childbearing Age: A Randomized Clinical Trial.

Authors:  Mark Weiser; Linda Levi; Daisy Zamora; Anat Biegon; John Paul SanGiovanni; Michael Davidson; Shimon Burshtein; Ilan Gonen; Paull Radu; Kristina Slobozean Pavalache; Igor Nastas; Rina Hemi; Timothy Ryan; John M Davis
Journal:  JAMA Psychiatry       Date:  2019-10-01       Impact factor: 21.596

Review 4.  Role of estrogen treatment in the management of schizophrenia.

Authors:  Jayashri Kulkarni; Emmy Gavrilidis; Roisin Worsley; Emily Hayes
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

5.  Oxytocin in schizophrenia: a review of evidence for its therapeutic effects.

Authors:  Kai Macdonald; David Feifel
Journal:  Acta Neuropsychiatr       Date:  2011-12-19       Impact factor: 3.403

6.  State-dependent effects of the D2 partial agonist aripiprazole on dopamine neuron activity in the MAM neurodevelopmental model of schizophrenia.

Authors:  Susan F Sonnenschein; Kathryn M Gill; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2018-09-18       Impact factor: 7.853

7.  Daily, weekly, seasonal and menstrual cycles in women's mood, behaviour and vital signs.

Authors:  Emma Pierson; Tim Althoff; Daniel Thomas; Paula Hillard; Jure Leskovec
Journal:  Nat Hum Behav       Date:  2021-02-01

8.  Menstrual Cycle in Schizophrenic Patients: Review with a Case.

Authors:  İpek Sönmez; Ferdi Köşger
Journal:  Noro Psikiyatr Ars       Date:  2015-12-01       Impact factor: 1.339

Review 9.  Sex steroids and schizophrenia.

Authors:  Julie A Markham
Journal:  Rev Endocr Metab Disord       Date:  2012-09       Impact factor: 6.514

10.  Estrogen and comprehension of metaphoric speech in women suffering from schizophrenia: results of a double-blind, placebo-controlled trial.

Authors:  Niels Bergemann; Peter Parzer; Susanne Jaggy; Beatrice Auler; Christoph Mundt; Sabine Maier-Braunleder
Journal:  Schizophr Bull       Date:  2007-12-21       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.